NCT06188195 Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS
| NCT ID | NCT06188195 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Second Affiliated Hospital of Chongqing Medical University |
| Condition | Acute Respiratory Distress Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2024-02-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. A predictive model for NARDS was established based on perinatal risk factors. Multivariate Logistic regression analysis was used to screen the independent prenatal risk factors for NARDS. A Logistic regression model was constructed using the above independent risk factors and quantified in a nomogram to construct a visualization model for prenatal prediction of NARDS. 2. The role of ACS in the prevention and treatment of ARDS in near-term/full-term infants. For neonates with a probability greater than 80% in the prediction model of ARDS, at least one ACS was given before the termination of pregnancy. The GC level of cord blood (taken at birth) and the mRNA levels of α-ENaC, Na-K-atpase and SGK1 in nasal epithelium were measured within 2 hours and 1 day after birth in the ACS intervention group and the control group. The occurrence and severity of pulmonary edema, the occurrence and severity of ARDS, and the mortality rate of NARDS were evaluated by lung ultrasound. The indexes of the two groups were compared horizontally and longitudinally.
Eligibility Criteria
A predictive model for neonatal acute respiratory distress syndrome was established based on perinatal risk factors. Inclusion Criteria: 1. The pregnant women with a probability greater than 80% in the prediction model of neonatal acute respiratory distress syndrome and agreed to ACS intervention. 2. Obtaining patient consent. Exclusion Criteria: 1. the pregnant women with a probability of less than 80% in the neonatal acute respiratory distress syndrome prediction model. 2. The patient refuses.
Contact & Investigator
Li Wang, MD,PhD
STUDY CHAIR
The Second Affiliated Hospital of Chongqing Medical University
Frequently Asked Questions
Who can join the NCT06188195 clinical trial?
This trial is open to female participants only, studying Acute Respiratory Distress Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06188195 currently recruiting?
Yes, NCT06188195 is actively recruiting participants. Contact the research team at liwang8771@126.com for enrollment information.
Where is the NCT06188195 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06188195 clinical trial?
NCT06188195 is sponsored by The Second Affiliated Hospital of Chongqing Medical University. The principal investigator is Li Wang, MD,PhD at The Second Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 500 participants.